Sangamo Therapeutics, Inc.SGMONASDAQ
LOADING
|||
Gross Profit Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
-96.83%
↓ 129% below average
Average (39q)
334.57%
Historical baseline
Range
High:13779.78%
Low:-317.31%
CAGR
+2.9%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -96.83% |
| Q2 2025 | 184.39% |
| Q1 2025 | -14.75% |
| Q4 2024 | -84.72% |
| Q3 2024 | 13779.78% |
| Q2 2024 | -25.99% |
| Q1 2024 | -76.44% |
| Q4 2023 | 104.28% |
| Q3 2023 | 9.01% |
| Q2 2023 | -155.32% |
| Q1 2023 | 343.24% |
| Q4 2022 | -0.76% |
| Q3 2022 | -26.16% |
| Q2 2022 | -0.95% |
| Q1 2022 | -27.45% |
| Q4 2021 | 29.82% |
| Q3 2021 | -5.34% |
| Q2 2021 | -6.83% |
| Q1 2021 | -13.54% |
| Q4 2020 | -312.87% |
| Q3 2020 | 162.47% |
| Q2 2020 | 29.69% |
| Q1 2020 | -271.91% |
| Q4 2019 | 215.30% |
| Q3 2019 | 24.21% |
| Q2 2019 | 29.40% |
| Q1 2019 | -317.31% |
| Q4 2018 | -22.28% |
| Q3 2018 | 33.05% |
| Q2 2018 | 28.15% |
| Q1 2018 | -73.17% |
| Q4 2017 | 4.73% |
| Q3 2017 | 1.75% |
| Q2 2017 | 29.27% |
| Q1 2017 | -91.57% |
| Q4 2016 | 64.98% |
| Q3 2016 | 9.95% |
| Q2 2016 | -39.10% |
| Q1 2016 | -5.68% |
| Q4 2015 | -31.88% |